Respiratory Medicine and Research最新文献

{"title":"Acute effects of fan therapy on exercise-induced breathlessness in healthy adults and people living with chronic respiratory disease: A systematic review","authors":"Julien Da Purificaçao ,&nbsp;Clémence Pierret ,&nbsp;Tristan Bonnevie ,&nbsp;William Poncin","doi":"10.1016/j.resmer.2025.101172","DOIUrl":"10.1016/j.resmer.2025.101172","url":null,"abstract":"<div><h3>Background</h3><div>Exercise-induced breathlessness is a common complaint in the general population and a highly prevalent symptom in adults living with chronic diseases, often acting as an important barrier to engaging in physical activity. Fan therapy can reduce breathlessness at rest, yet its acute effects during exercise have not been systematically explored.</div></div><div><h3>Methods</h3><div>A literature search encompassing three electronic databases (PubMed, Scopus, Embase) from inception to January 2025 was conducted to identify randomized controlled trials comparing fan therapy during and after an acute exercise bout to a control condition, on dyspnea and exercise capacity. Relevant conference abstracts were considered. Risk of bias was assessed via the Physiotherapy Evidence Database scale. The PRISMA guidelines were followed.</div></div><div><h3>Results</h3><div>A total of six studies, including one conference abstract, met eligibility criteria. Five records involved 79 adults with chronic respiratory disease, all presenting a respiratory disease, and the remaining record included 10 healthy individuals. The results were generally consistent, showing that fan therapy significantly reduces exercise-induced breathlessness (<em>n</em> = 2 studies), decreases breathlessness during recovery (<em>n</em> = 5), and enhances exercise capacity (<em>n</em> = 2). The methodological quality was good for half or retrieved studies and poor-to-fair in the other half.</div></div><div><h3>Conclusion</h3><div>Fan therapy might relieve dyspnea and improve exercise capacity during and after an acute bout of exercise in patients with chronic respiratory disease. Future high-quality research should confirm these findings and consider assessing fan therapy effects in other populations. PROSPERO number: CRD42023475117</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101172"},"PeriodicalIF":2.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Mi-2 positive interstitial lung disease (ILD): A progressive disease comparable to other myositis-ILD","authors":"Bess M. Flashner ,&nbsp;Ryosuke Imai ,&nbsp;Andrew J. Synn ,&nbsp;Julia K. Munchel ,&nbsp;Lida P. Hariri ,&nbsp;Fiona K. Gibbons ,&nbsp;Sydney B. Montesi ,&nbsp;Barry S. Shea ,&nbsp;Mary B. Rice ,&nbsp;Rene S. Bermea ,&nbsp;Robert W. Hallowell","doi":"10.1016/j.resmer.2025.101176","DOIUrl":"10.1016/j.resmer.2025.101176","url":null,"abstract":"<div><h3>Background</h3><div>Evaluation for interstitial lung disease (ILD) often involves sending a myositis panel that includes myositis-associated and myositis-specific antibodies (MAA and MSA respectively) such as anti-Mi-2. Little is known about anti-Mi-2 positive ILD. We sought to determine the typical presentation and prognosis of anti-Mi-2 positive ILD.</div></div><div><h3>Methods</h3><div>We performed a retrospective chart review of patients in two ILD referral centers in Boston, MA with a positive anti-Mi-2 antibody between 2012 and 2024. Patients were identified by query of the medical record for patients with anti-Mi-2, and we included those with ILD on chest computed tomography (CT). We conducted survival analyses for ILD progression-free and overall survival using Kaplan-Meier curves and log-rank tests. Additionally, a Cox proportional-hazards model was employed, adjusting for age, gender, baseline forced vital capacity, and immunosuppressant use to calculate hazard ratios. The comparator group included patients who were followed longitudinally in the ILD clinic who were anti-Mi-2 negative but positive for other MSAs.</div></div><div><h3>Results</h3><div>Fifty-eight patients were identified. Half (52 %) were female with mean age 67 years (SD 13 years). The majority had dyspnea and/or cough, and a quarter of patients required oxygen upon presentation. Six (10 %) had PM/DM that pre-dated their ILD diagnosis. Other autoantibody positivity was common; one-third-of patients (<em>n</em> = 19, 33 %) were positive for anti-Mi-2 alone without positivity for other MSAs or MAAs. Clinical follow up data were available for 52 patients for a median follow up of 24 months (range &lt;1 month-10 years). PFT progression was seen in 67 % and radiologic progression was seen in over a third. Half received immunosuppression (55 %), with 19 % requiring multiple immunosuppressives. During follow up, 21 % had acute exacerbation of ILD or death. Progression-free and overall survival were not significantly different among anti-Mi-2 positive ILD <em>versus</em> anti-Mi-2 negative, MSA positive ILD patients regardless of anti-Mi-2 positivity alone or in combination with other autoantibodies.</div></div><div><h3>Conclusions</h3><div>This series of 58 patients is the largest anti-Mi-2 positive ILD cohort to date. Concurrent positivity with other autoantibodies associated with ILD was common. Anti-Mi-2 positive ILD was associated with similar outcomes to those with other MSAs. Larger studies are needed to better characterize patients with Mi-2 positive ILD.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101176"},"PeriodicalIF":2.2,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144177511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020","authors":"Sébastien Couraud ,&nbsp;Olivier Molinier ,&nbsp;Marielle Sabatini ,&nbsp;Séverine Thomassin ,&nbsp;Rym Haouachi ,&nbsp;Virginie Levrat ,&nbsp;Hannah Ghalloussi-Tebai ,&nbsp;Antoine Belle ,&nbsp;Laurent Mosser ,&nbsp;Sébastien Larive ,&nbsp;Alexandra Bedossa ,&nbsp;Alexia Letierce ,&nbsp;Hugues Morel ,&nbsp;Didier Debieuvre ,&nbsp;Study Group KBP-2020-CPHG","doi":"10.1016/j.resmer.2025.101174","DOIUrl":"10.1016/j.resmer.2025.101174","url":null,"abstract":"<div><h3>Introduction</h3><div>Cannabis smoking is suspected to be a risk factor for lung cancer. The KBP-2020-CPHG study is a prospective study that collected data from all patients with newly diagnosed lung cancer in non-academic hospitals in France in 2020.</div></div><div><h3>Method</h3><div>We conducted comparative and matched cohort analyses using the dataset, in which cannabis smokers (i.e. participants who self-declared a lifetime intake of ≥20 joints) were compared with tobacco-only smokers. After matching on confounders, we compared age at diagnosis and overall survival.</div></div><div><h3>Results</h3><div>Among 8999 patients, 314 (3.6%) were cannabis smokers and 7372 were tobacco-only smokers (data missing for 183). Cannabis smokers were younger than tobacco-only smokers at lung cancer diagnosis (mean [± standard deviation] 52.9 [±8.84] <em>versus</em> 67.7 [±9.51] years; p&lt;0.0001), and this difference remained in the paired analysis (matched for histology, sex and cigarette pack-years [±5 pack-years]; n = 298 pairs; median age at diagnosis 53.1 <em>vs</em> 64.8 years; hazard ratio 5.61, 95% CI 4.10–7.68; p&lt;0.0001). Histological type was also different between the two groups, with more cases of adenocarcinoma and large cell neuroendocrine carcinoma among cannabis smokers. Finally, a 1:1 matched analysis controlled for age, sex, stage, histology and cigarette pack-years showed that overall survival was not affected by cannabis smoking (HR 0.90, 95% CI 0.68–1.18; p = 0.44).</div></div><div><h3>Conclusion</h3><div>We provide a detailed description of lung cancer characteristics among cannabis smokers compared with tobacco-only smokers. Cannabis smoking appeared to be associated with lung cancer diagnosis at an earlier age and was not a prognostic factor for mortality.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101174"},"PeriodicalIF":2.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe respiratory syncytial virus infection in older adults – burden, clinical outcomes and implications for care","authors":"Daniel Guimarães de Oliveira ,&nbsp;Ana Grande ,&nbsp;Francisco Belchior ,&nbsp;Rafaela Costa ,&nbsp;Rita Francisco ,&nbsp;Natália Oliveira ,&nbsp;Maria Calle","doi":"10.1016/j.resmer.2025.101173","DOIUrl":"10.1016/j.resmer.2025.101173","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory syncytial virus (RSV) infection in adults remains under-researched. Increased testing is revealing an emerging picture of severe outcomes within the most prevalent lower respiratory tract infections. Understanding risk factors is increasingly important, especially in light of the recent approval of prophylactic vaccination.</div></div><div><h3>Methods</h3><div>Retrospective evaluation of all real-time polymerase chain reaction-positive RSV cases detected at our institution over three consecutive infection seasons from 2021 to 2024 in adults aged 60 years and older. Subsequent assessment of patients with severe infection requiring hospitalization.</div></div><div><h3>Results</h3><div>A total of 574 individuals were included, 57 % of whom were female, with a median age of 81,1 years (IQR 74–87 years). The peak number of cases occurred between September and March. We found a hospitalization rate of 51,2 % (representing an incidence of 1 case per 758 inhabitants per year in the elderly population of our region) and an in-hospital mortality rate of 15,6 % (19,1 % if transferred patients are excluded) among older adults with PCR-confirmed RSV infection. Heart failure (<em>p</em> ≤ 0.001), asthma (<em>p</em> = 0005), chronic kidney disease (<em>p</em> = 0006), chronic obstructive pulmonary disease (<em>p</em> = 0,02) and active smoking (<em>p</em> = 0.01) were risk factors for hospitalization. Older age (<em>p</em> = 0.003), residing in long-term care facility (<em>p</em> = 0.003), active cancer (<em>p</em> = 0,01), lower lymphocytes (<em>p</em> ≤ 0,001) and higher creatinine (<em>p</em> = 0,01) were significantly associated with mortality.</div></div><div><h3>Conclusions</h3><div>This is the first review of health outcomes related to RSV infection in the elderly from a Portuguese hospital. It identifies a high burden of hospitalization and in-hospital mortality in the elderly population. Our findings highlight the need for increased awareness of RSV infection in adults, particularly older adults, and underscore the importance of targeted interventions, such as vaccination programs, to reduce the burden of this disease in vulnerable populations in Portugal.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101173"},"PeriodicalIF":2.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of inhaled corticosteroids on metabolic dysfunction-associated steatotic liver disease risk in COPD patients","authors":"Jiyu Sun ,&nbsp;Hyo Jin Lee ,&nbsp;Jung-Kyu Lee ,&nbsp;Tae Yeon Park ,&nbsp;Eun Young Heo ,&nbsp;Deog Kyeom Kim ,&nbsp;Hyun Woo Lee","doi":"10.1016/j.resmer.2025.101171","DOIUrl":"10.1016/j.resmer.2025.101171","url":null,"abstract":"<div><h3>Background</h3><div>The systemic impact of long-term use of inhaled corticosteroid (ICS) on the liver remains poorly understood in patients with chronic obstructive pulmonary disease (COPD). Our study aimed to identify whether long-term ICS therapy impacts the risk of Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with COPD.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted using claims records from a large population-based database. We included COPD patients ≥40 years old who had no previous history of chronic liver disease. Patients were divided into two groups based on their ICS use. The primary outcome was the development of MASLD. Additionally, subgroup analyses were conducted according to the duration of ICS exposure and the various components of ICS.</div></div><div><h3>Results</h3><div>A total of 442,880 COPD patients were included in the study, with 95,695 in ICS group and 347,185 in non-ICS group. The incidence rate of MASLD was higher in the ICS group compared to the non-ICS group (859.3 vs<em>.</em> 440.4 per 100,000 person-years). After adjusting for potential confounding factors, ICS use was associated with a significantly increased risk of MASLD (hazard ratio [HR]=1.630, 95 % confidence interval [CI]=1.560–1.704). Fluticasone furoate showed a higher risk of MASLD compared to other ICS components, and a longer duration of ICS exposure was associated with an increased MASLD risk.</div></div><div><h3>Conclusions</h3><div>In COPD patients, long-term use of ICS may be associated with an increased risk of developing MASLD. Further studies are needed to explore strategies to mitigate the potential risk of MASLD in COPD patients requiring ICS therapy.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101171"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolution of management in chronic thromboembolic pulmonary hypertension in a non-surgical / balloon pulmonary angioplasty center","authors":"Mitja Jevnikar,&nbsp;David Montani,&nbsp;Elie Fadel,&nbsp;Xavier Jais","doi":"10.1016/j.resmer.2023.101043","DOIUrl":"10.1016/j.resmer.2023.101043","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101043"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77233336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of guidelines for management of Community Acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF)","authors":"Aurélien Dinh ,&nbsp;François Barbier ,&nbsp;Jean-Pierre Bedos ,&nbsp;Mathieu Blot ,&nbsp;Vincent Cattoir ,&nbsp;Yann-Erick Claessens ,&nbsp;Xavier Duval ,&nbsp;Pierre Fillâtre ,&nbsp;Maxime Gautier ,&nbsp;Yann Guegan ,&nbsp;Sophie Jarraud ,&nbsp;Alban Le Monnier ,&nbsp;David Lebeaux ,&nbsp;Paul Loubet ,&nbsp;Constance de Margerie ,&nbsp;Philippe Serayet ,&nbsp;Yacine Tandjaoui-Lambotte ,&nbsp;Emmanuelle Varon ,&nbsp;Yves Welker ,&nbsp;Damien Basille","doi":"10.1016/j.resmer.2025.101161","DOIUrl":"10.1016/j.resmer.2025.101161","url":null,"abstract":"<div><div>Community-Acquired Pneumonia (CAP) of Presumed Bacterial Origin: Updated Management Guidelines</div><div>Community-acquired pneumonia (CAP) of presumed bacterial origin is a common condition with varying severity, requiring either outpatient, hospital, or even critical care management.</div><div>The French Infectious Diseases Society (SPILF) and the French Language Pulmonology Society (SPLF), in collaboration with the French Societies of Microbiology (SFM), Emergency Medicine (SFMU), Radiology (SFR), and Intensive Care Medicine (SRLF), along with representatives of general practice, have coordinated an update of the previous management guidelines, which dated back to 2010.</div><div>From a therapeutic perspective, the updated recommendations define the choice of initial empiric antibiotic therapy, indications for combination therapy, the use of anti-Pseudomonas beta-lactams, antibiotic treatment duration, and the indications and modalities for prescribing systemic corticosteroids.</div><div>On a biological level, indications for biomarkers and microbiological investigations have been refined. Regarding imaging, the role of different modalities in the diagnosis and follow-up of CAP has been reassessed, including chest X-ray, pleuropulmonary ultrasound, and thoracic CT scan</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101161"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Arterial Hypertension-approved drugs in Pulmonary Hypertension associated with COPD: A systematic literature review","authors":"Beatrice Le Bon Chami ,&nbsp;Fida Charif ,&nbsp;Claude Semaan ,&nbsp;Vanessa Bironneau ,&nbsp;Elisa Larrieu-Ardilouze ,&nbsp;Magali Croquette ,&nbsp;Xavier Jaïs ,&nbsp;Lucilla Piccari ,&nbsp;David Montani ,&nbsp;Etienne-Marie Jutant","doi":"10.1016/j.resmer.2025.101165","DOIUrl":"10.1016/j.resmer.2025.101165","url":null,"abstract":"<div><h3>Introduction</h3><div>Pulmonary hypertension (PH) is commonly associated with chronic obstructive pulmonary disease (COPD), with an estimated prevalence of 39%. PH reduces functional capacity and exercise tolerance, and increases the risk of COPD exacerbations and hospitalizations. PH associated with COPD (PH–COPD) typically manifests with moderate severity, progressing gradually in tandem with the level of bronchial obstruction. However, a specific subgroup with severe PH displays disproportionately high pulmonary vascular resistance, reduced diffusion capacity, and a severe prognosis.</div></div><div><h3>Methods</h3><div>This article is a systematic literature review of clinical trials including randomized controlled trials (RCTs), non-RCTs, cohort studies and registry data regarding PAH-approved drugs, in the context of PH–COPD, from January 2003 to January 2025.</div></div><div><h3>Results</h3><div>There have been three positive and three negative RCTs with phosphodiesterase-5 inhibitors, as well as one positive and one negative RCT with endothelin receptor antagonists. These RCTs suffered from limitations especially in severe PH cases. Additional data came from 16 studies, including non-RCTs, cohort studies and registry data, and the results were conflicting. The most robust study, a large phase 3 RCT using inhaled treprostinil, was terminated early due to an unfavorable benefit-risk ratio.</div></div><div><h3>Conclusion</h3><div>The evidence does not support PAH-approved drugs for mild-to-moderate PH–COPD, though potential benefits may exist for the severe PH subgroup. Large, multicenter RCTs are necessary to provide robust medical evidence and phase 2 and phase 3 clinical trials are ongoing. In the interim, suspected or confirmed severe PH–COPD should prompt referral to PH centers for personalized care and potential clinical trial participation.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101165"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143898531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive course of anti-nuclear matrix protein-2 (NXP-2) positive-interstitial lung disease","authors":"Bess M. Flashner ,&nbsp;Ryosuke Imai ,&nbsp;Andrew J. Synn ,&nbsp;Julia K. Munchel ,&nbsp;Lida P. Hariri ,&nbsp;Fiona K. Gibbons ,&nbsp;Sydney B. Montesi ,&nbsp;Barry S. Shea ,&nbsp;Mary B. Rice ,&nbsp;Rene S. Bermea ,&nbsp;Robert W. Hallowell","doi":"10.1016/j.resmer.2025.101170","DOIUrl":"10.1016/j.resmer.2025.101170","url":null,"abstract":"<div><h3>Background</h3><div>Evaluating the etiology of interstitial lung disease (ILD) commonly involves ordering a myositis panel containing myositis-specific antibodies (MSAs), including anti-NXP-2. However, little is known about the presentation of patients with ILD and anti-NXP-2 positivity. We sought to define the course of anti-NXP-2-positive ILD in order to guide prognosis and potential treatment strategies.</div></div><div><h3>Methods</h3><div>We performed a retrospective chart review of patients with positive anti-NXP-2 antibodies who presented to two ILD referral centers in Boston, MA between 2012 and 2024. Patients were identified by query of the electronic medical record for patients positive for anti-NXP-2. We included those anti-NXP-2 positive patients with ILD on chest computed tomography (CT). Data regarding clinical presentation and disease course were abstracted from the medical record. For patients following longitudinally in the ILD clinic, we conducted survival analyses for ILD progression (composite of PFT progression, hospitalization, or death) using Kaplan-Meier curves and log-rank tests. Additionally, we used a Cox proportional-hazards model, adjusting for age, gender, forced vital capacity (FVC) at baseline, and immunosuppression to calculate hazard ratios. ILD patients with MSA-positive, NXP-2-negative ILD served as the comparator group.</div></div><div><h3>Results</h3><div>31 patients were identified (mean 70 years, SD 9). Three were diagnosed with dermatomyositis (DM) prior to presentation, but the remaining had ILD as the only manifestation of connective tissue disease. Most (97%) patients were symptomatic with dyspnea and/or cough at presentation. Other autoantibody positivity was common; only 42% were positive for anti-NXP-2 alone without positivity for other autoimmune serologies, including MSAs known to be associated with ILD. Clinical follow up data were available for 28 patients for a median follow up period of 24 months (range &lt;1 month-13 years). A majority (61%) were treated with immunosuppression, antifibrotics, or both. Over one third experienced acute exacerbation of ILD or death (<em>N</em> = 11, 35%). Progression-free survival was similar to that of other MSA-positive ILD patients, regardless of whether anti-NXP-2 was positive alone or co-positive for other autoantibodies.</div></div><div><h3>Conclusions</h3><div>We present the largest single series of anti-NXP-2-positive ILD. Anti-NXP-2-positive ILD can occur in the absence of DM/PM and can manifest as progressive pulmonary disease that is similar to other MSA-positive ILDs.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101170"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of non-small cell lung cancer after 2 years of immunotherapy","authors":"Cédric Mahiat ,&nbsp;Jacques Cadranel ,&nbsp;Constance Méteyé ,&nbsp;Samy Houari ,&nbsp;Lise Rosencher ,&nbsp;Christelle Epaud ,&nbsp;Jérémy Slomka ,&nbsp;Vincent Fallet ,&nbsp;Anthony Canellas","doi":"10.1016/j.resmer.2025.101169","DOIUrl":"10.1016/j.resmer.2025.101169","url":null,"abstract":"<div><h3>Background</h3><div>The optimal management strategy for metastatic or advanced-stage non-small-cell lung cancer (NSCLC) after 2 years of immune checkpoint inhibitor (ICI) remains unclear.</div></div><div><h3>Methods</h3><div>We conducted a single-center retrospective observational study to characterize the management of patients who received at least 2 years of ICI in the first-line setting for a metastatic or advanced-stage NSCLC.</div></div><div><h3>Results</h3><div>Among the 254 patients that received ICI in the first-line setting, 39 (15%) achieved 2 years of treatment (ICI in monotherapy, <em>n</em> = 14; ICI with chemotherapy, <em>n</em> = 25). ICI was discontinued after 2 years (&lt;30 months) in 31 (79%) of the cases. During the first 2 years, 29 patients (74%) had no disease progression (2 complete radiological responses, 25 partial radiological responses, and 2 stable diseases) and 10 patients (26%) experienced at least one oligo-progression, which was treated with local ablative treatment (LAT), allowing continuation of ICI up to 2 years. A positron emission tomography (PET) scan was performed at 2 years for 37 patients (95%), revealing a complete metabolic response (CMR) in 16 individuals (43%). None of these patients progressed subsequently (median follow-up: 13 months). After 2 years of ICI, the 12-month progression-free survival was 100% in case of CMR versus 49% (95% CI, 29–91) in the absence of CMR (<em>p</em> = 0.00037).</div></div><div><h3>Conclusions</h3><div>A CMR at 2 years of ICI is associated with a favorable prognosis. Further studies are needed to better establish the role of PET scan at 2 years, the relevance of LAT and the optimal duration of ICI.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101169"},"PeriodicalIF":2.2,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143808117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}